The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials

European Urology
Richard J SylvesterJ Alfred Witjes

Abstract

Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; however, the optimal schedule and duration of treatment are unknown. The objective is to determine the effect of schedule and duration of intravesical chemotherapy on recurrence in patients with stage Ta T1 bladder cancer. A systematic review was conducted of the published results of randomized clinical trials that compared intravesical instillations with respect to their number, frequency, timing, duration, dose, or dose intensity. One immediate instillation after transurethral resection (TUR) is recommended in all patients. In low-risk patients, no further treatment is recommended before recurrence. In patients with multiple tumors, one immediate instillation is insufficient treatment. Additional instillations may further reduce the recurrence rate; however, no recommendations can be made concerning their optimal duration. A short intensive schedule of instillations within the first 3-4 mo after an immediate instillation may be as effective as longer-term treatment schedules (grade C). Instillations during > or =1 yr in intermediate-risk patients seem advisable only when an immediate instillation has not been given (grade C). Higher drug conc...Continue Reading

References

Jan 1, 1983·Cancer Chemotherapy and Pharmacology·Tadao NiijimaHideyuki Akaza
Apr 21, 1999·The Journal of Urology·J R MastersM K Parmar
Apr 20, 2001·Journal of the National Cancer Institute·J L AuInternational Mitomycin C Consortium
Oct 18, 2001·Journal of the National Cancer Institute·J R Masters
Apr 15, 2004·European Urology·Gerhard JakseWillem Oosterlinck
Mar 7, 2006·The Journal of Urology·Taner DivrikHaluk Ozen

Citations

Feb 1, 2013·PloS One·Michelle AgenantJ L H Ruud Bosch
Feb 15, 2012·Der Urologe. Ausg. A·F Vom DorpG Lümmen
May 31, 2012·Advances in Urology·Daniel A BarocasRachel J Spear
May 13, 2008·European Urology·Marko BabjukEuropean Association of Urology (EAU)
Oct 17, 2014·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Teng LiMin Chen
Oct 23, 2008·Journal of Cancer Research and Clinical Oncology·Christian BolenzMaurice Stephan Michel
Nov 30, 2010·Expert Review of Anticancer Therapy·Rianne J M Lammers, J Alfred Witjes
Oct 4, 2012·Expert Review of Anticancer Therapy·Willem Oosterlinck, Karel Decaestecker
Jun 14, 2008·Expert Opinion on Investigational Drugs·J Alfred Witjes, Prasad S Kolli
Nov 19, 2009·Journal of Pharmaceutical Sciences·Jia-You FangChao-Huang Chen
Jul 5, 2016·Bladder Cancer·Nicholas E Power, Jonathan Izawa
Feb 4, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·C PfisterLes membres du CCAFU
Jul 6, 2013·European Urology·Marko BabjukEuropean Association of Urology
Mar 6, 2012·Actas urologicas españolas·Marko BabjukAsociación Europea de Urología
May 6, 2011·European Journal of Radiology·Yuki KanazawaOsamu Sato
Apr 5, 2011·European Urology·Marko BabjukEuropean Association of Urology (EAU)
Mar 30, 2010·BJU International·Paolo PuppoAURO.it guideline committee
Feb 3, 2010·BJU International·Benjamin E AyresAction for Bladder Cancer
Mar 17, 2015·Expert Opinion on Pharmacotherapy·Sanjay G PatelGary D Steinberg
Dec 21, 2010·European Urology·Willem OosterlinckEuropean Association of Urology Guidelines Committee on Non-Muscle-Invasive Bladder Tumors
Jul 16, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takuo MaruyamaHiroki Shima
Apr 4, 2015·Hematology/oncology Clinics of North America·Yme WeijersJ Alfred Witjes
Jun 22, 2016·European Urology·Marko BabjukRichard Zigeuner
Jan 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashish M KamatJ Alfred Witjes
Dec 2, 2015·Therapeutic Advances in Urology·Vincenzo PagliaruloArcangelo Pagliarulo
Mar 13, 2018·Expert Review of Anticancer Therapy·Willem Oosterlinck, Karel Decaestecker
May 8, 2018·Expert Opinion on Emerging Drugs·Jasper Crijnen, Theo M De Reijke
Jul 2, 2014·Nature Reviews. Urology·Laura S MertensBas W G van Rhijn
Apr 6, 2013·Urologia·Vittorino MontanaroVincenzo Altieri
Oct 8, 2016·Urologia·Vincenzo SerrettaGiovanni Caruana
Aug 24, 2018·Current Opinion in Urology·Mohammad AbufarajMarek Babjuk
Aug 2, 2008·Current Opinion in Urology·Joerg Schmidbauer, Gabriele Lindenau
Mar 9, 2010·Expert Opinion on Pharmacotherapy·Steve K WilliamsMark Soloway
Aug 5, 2011·Current Opinion in Urology·Johannes Falke, J Alfred Witjes
Aug 16, 2018·World Journal of Urology·Leonardo L MonteiroWassim Kassouf
May 2, 2020·World Journal of Urology·Jeremy Y C TeohThomas Herrmann
Mar 24, 2021·Deutsches Ärzteblatt International·Maike de WitJürgen E Gschwend

Related Concepts

Intravesical Injection
Antineoplastic Agents
Malignant Neoplasm of Urinary Bladder
Drug Administration Schedule
Neoplasm Recurrence, Local
TNM Staging System
Urinary Bladder
Objective (Goal)
Treatment Protocols
Clinical Trials, Randomized

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.